Latest Breaking News On - Us pass agency shanghai - Page 1 : comparemela.com

英矽智能任命Robert Spiegel博士担任代理首席医学官-美通社PR-Newswire

英矽智能任命Robert Spiegel博士担任代理首席医学官-美通社PR-Newswire
prnasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnasia.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesNew york universityYale universityBoard of directors officeScience consultant committeeA new york universityUs pass agency shanghaiSenior management officePennsylvania universityUnited states national health instituteAgency shanghaiResearch directorDirectors office

战略合作达成，德琪医药和上药控股强强联合，全面提速商业化布局-美通社PR-Newswire

上海和香港2021年8月13日 /美通社/ 2021年8月12日，德琪医药与上药控股就全球首款口服型选择性核输出抑制剂塞利尼索（美国食品药品管理局批准的专用英文商品名：XPOVIO® ，英文通..

United statesMatilda qiLee yongzhongHong kong augustUs pass agency shanghaiB holdingsLee yongzhong holdingsAgency shanghaiEnglish universalLixin shanghaiExecutive directorInnovation financeChina countryMay keminProfessional academicLee yongzhong shanghai

德琪医药荣膺 2021年中国医药新锐创新力量企业-美通社PR-Newswire

德琪医药荣膺 2021年中国医药新锐创新力量企业-美通社PR-Newswire
prnasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnasia.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaHong kong augustUs pass agency shanghaiGenesis chile country forum wiseRd centerMission germany qiIndustrial researchAgency shanghaiIndustrial research general hospitalAnnual meetingChina genesisChile genesis newGreater china marketAsia pacific marketShanghai zhangjiang

全球首款口服型XPO1抑制剂塞利尼索在韩优先获批上市，德琪医药加速创新药国际化战略布局-美通社PR-Newswire

全球首款口服型XPO1抑制剂塞利尼索在韩优先获批上市，德琪医药加速创新药国际化战略布局-美通社PR-Newswire
prnasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnasia.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesHong kongJing qiHong kong augustBristol myers squibbUs pass agency shanghaiAssociation clinicAgency shanghaiEnglish universalGenesis newUnited states countryAssociation clinic guideAsia pacific marketCross countryGreater china market

首届中国血液东方峰会暨德琪血液高峰论坛在上海召开-美通社PR-Newswire

华中科技大学同济医学院附属协和医院院长胡豫教授；北京大学血液病研究所所长黄晓军教授；中华医学会血液学分会常委李建勇教授；南方医科大学血液病研究所所长刘启发教授；哈尔滨血液病肿瘤研究所所长马军教授；中国医学科学院血液病医院淋巴瘤诊疗中心主任邱录贵教授；上海交通大学附属瑞金医院内科学终身教授沈志祥教授；中国医学科学院血液病医院副所院长王建祥教授；苏州大学附属第一医院血液科主任吴德沛教授；上海交通大学医学院附属瑞金医院副院长赵维莅教授（以姓氏汉语拼音为序）共同担任本次大会主席，并负责各环节的主持。第一篇章：多发性骨髓瘤的复发不可避免，巩固和维持治疗是重中之重 [1]。据最新数据统计，中国 MM 发病率为 1.6/10 万 [2]，死亡人数为 146554 ，且发病率呈逐年增高状态和年轻化趋势 [3]。�

United statesHong kongLee xiaoqiu gandhiClinic centerProfessor shen zhixiang china medical academyShanghai transport university medicineRd centerBranch standing committee lee jianyong professor southService germany qiPeak forum on shanghaiChina medical academyWu professor shanghai transport university medicineQi polya churchSuzhou universityMa professor china medical academyUs pass agency shanghai